What is already known about this topic?
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as a new class of cholesterol lowering drugs, have been approved for treating hyperlipidemia in China 2019. The efficacy and safety of PCSK-9 inhibitors were confirmed by several clinical trials, but its effectiveness in routine clinical practice in China is unknown.